METHODS OF CELL DELIVERY
- Direct Myocardial Injection
- Transcatheter Endomyocardial Injection
- Intracoronary Cell Injection
- Intravenous Cell Injection
- Intramyocardial Injection via Coronary Vein
Cardiac disease is still the primary cause of mortality in the world. An estimate shows that 17.3 million people died from CVDs in 2014, representing 30% of all global deaths. The number of people who die from CVDs, mainly from heart disease and stroke, will increase to reach 23.3 million by 2030.
Group of Disorders of Heart and Blood vessels
Coronary heart disease
Peripheral arterial disease
Rheumatic heart disease
In the absence of effective endogenous or drug induced repair mechanisms following cardiac injury, cell-based therapies have rapidly emerged as potential novel therapies to treat myocardial failure.
Risk factors associated with various therapies include discomfort and bleeding, blood vessel damages, arrhthymia kidney damage. STEM CELL Therapy could potentially repair and regenerate damaged heart tissue.
Umbilical Cord Blood Cells
Patients with CAD and Ejection fraction below 50% are good candidates. EECP 30 to 40 cycle plus 3 autologus stem cells IV infusions given. Stem Cells are injected/ infused IV at 7 days intervals. EF improved by 10% to 15% over the average EECP improvements. EF improvement visible in 85% of the cases in the study group.